Turning waste into sustainable scaffolds for synthesis
High-throughput screening is a powerful tool to start drug-discovery programs. The success of this activity is highly dependent on the quality of the library that is screened. With this in mind, Symeres created the SymeGold library, which features compounds with a high degree of three-dimensionality.
Symeres welcomes Dr. André de Vries
At Symeres, we’re always looking to support our clients with novel and innovative ideas. Dr. André de Vries joined our ranks as of January 1, 2022.
Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II
In 2016, Stefan Krauss and Jo Waaler (University Hospital of Oslo, Norway) approached Symeres to optimize […]
Chiralix, a Symeres company
Richard Baauw joined Symeres in 2017, along with his company Chiralix. Chiralix focused on the synthesis of optically active compounds.
